Antalya Training and Research Hospital
Antalya, 07100, Turkey (Türkiye)
NCT Number: NCT07493525
This cross-sectional observational study aims to determine the frequency of falls in patients with myotonic dystrophy type 1 and to identify factors affecting dynamic balance. The study will also evaluate fear of falling, selected lower extremity muscle strength, and the relationship between muscle strength and fall frequency. The findings may contribute to a better understanding of fall risk and balance impairment in patients with myotonic dystrophy type 1.
This study is active but is not currently recruiting participants.
18 year–60 year
All sexes
Observational
Antalya, 07100, Turkey (Türkiye)
Myotonic dystrophy type 1 is a multisystem neuromuscular disorder characterized by myotonia, progressive muscle weakness, and functional limitations. Distal muscle weakness, impaired postural control, and gait dysfunction may increase the risk of falls and negatively affect daily activities and quality of life. Although falls and balance impairment are clinically important in patients with myotonic dystrophy type 1, data on fall frequency and factors affecting dynamic balance remain limited.
This single-center, hospital-based, cross-sectional observational study will be conducted in patients with myotonic dystrophy type 1 who are followed at the Neuromuscular Diseases Center of Antalya Training and Research Hospital. The study aims to determine fall frequency and to investigate factors affecting dynamic balance. Fear of falling, lower extremity muscle strength, and dynamic balance performance will be assessed, and the relationship between muscle strength and fall frequency will be examined. The results are expected to improve the understanding of fall-related impairments in myotonic dystrophy type 1 and support more comprehensive clinical assessment and rehabilitation planning.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline
Fall frequency will be assessed using semi-structured questions regarding the number of falls experienced by patients with myotonic dystrophy type 1.
Time frame: At baseline
Fear of falling will be assessed using semi-structured questions regarding the fear of falling experienced by patients with myotonic dystrophy type 1.
Time frame: At baseline
Disease-related muscle involvement severity will be assessed using the Muscular Impairment Rating Scale (MIRS).
Time frame: At baseline
Dynamic balance performance will be assessed using the Timed Up and Go (TUG) test.
Time frame: At baseline
Walking performance and dynamic mobility will be assessed using the 10-Meter Walk Test at maximum safe speed.
Time frame: At baseline
Isometric muscle strength of selected muscle groups will be measured to evaluate the relationship between muscle strength and fall frequency.
Time frame: At baseline
Hand grip strength will be measured using a hand grip strength assessment.
Time frame: At baseline
Balance performance will be evaluated using the Berg Balance Scale.
Time frame: At baseline
Ambulation level will be recorded using the Functional Ambulation Scale (FAS).
Antalya Training and Research Hospital
Other Gov
Determination of Fall Frequency and Factors Affecting Dynamic Balance in Patients With Myotonic Dystrophy Type 1: A Cross-Sectional Observational Single-Center Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07700225
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Richmond, Virginia, United States
View Trial DetailsNCT06316778
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jonquière, Quebec, Canada
View Trial DetailsNCT02312011
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Stanford, California, United States
View Trial DetailsNCT02831504
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Newcastle upon Tyne, Tyne and Wear, United Kingdom
View Trial Details